Evotec receives $ 6 million from Bristol Myers Squibb. Payment is made as part of an alliance between the two companies. Bristol Myers Squibb has added an additional drug discovery project to its joint portfolio. That triggered the payment.
The alliance has existed since 2016. The aim is to find disease-modifying therapy options for neurodegenerative diseases. Here you can see a high demand.
Evotec brings a technology platform to the partnership. Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted with this addition to our joint portfolio with Bristol Myers Squibb, which further validates the iPSC-based approach in our strategic neurology partnership. We are certain that iPSC-based approaches will deliver drug candidates with better disease relevance and thus lead to safer and more effective drugs than conventional approaches. “